Best Practice and Research. Clinical Obstetrics and Gynaecology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Endometrial Cancer Prevention in High Risk Women
Publication date: Available online 20 December 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Kelechi Njoku, Joanna Abiola, Johanna Russell, Emma J. CrosbieAbstractEndometrial cancer is the most common gynaecological malignancy and its incidence is rising alongside the growing prevalence of obesity. Effective risk reducing interventions hijacking the key mechanisms driving endometrial carcinogenesis may reduce endometrial cancer diagnoses if aimed at those at greatest risk. An understanding of the key risk factors and their role in tumourigenesis is critical in developing such prevention s...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - December 21, 2019 Category: OBGYN Source Type: research
Preface: Volume 65
Publication date: Available online 17 December 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Wendy Marder, Timothy R.B. Johnson (Source: Best Practice and Research Clinical Obstetrics and Gynaecology)
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - December 18, 2019 Category: OBGYN Source Type: research
Male and female condoms: Their key role in pregnancy and STI/HIV prevention
Publication date: Available online 14 December 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Mags Beksinska, Rachel Wong, Jenni SmitAbstractMale and female condoms are the only available multi-purpose technology (MPT) that can prevent unintended pregnancy and sexually transmitted infections including HIV. If used correctly and consistently, condoms can provide levels of pregnancy protection similar to many hormonal methods. Condoms remain one of the most common methods used at first sexual intercourse and are relied on as a current use of contraception by adolescents in many regions of th...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - December 14, 2019 Category: OBGYN Source Type: research
Breast cancer prevention in high-risk women
Publication date: Available online 21 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Mangesh A. Thorat, Rajeshkumar BalasubramanianAbstractWomen at high risk of developing breast cancer are a heterogeneous group of women including those with and without high-risk germline mutation/s. Prevention in these women requires a personalised and multidisciplinary approach. Preventive therapy with selective oestrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors (AIs) substantially reduces breast cancer risk well beyond the active treatment period. The importance of be...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - December 12, 2019 Category: OBGYN Source Type: research
Risk-based breast cancer screening strategies in women
Publication date: Available online 18 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Elaine F. Harkness, Susan M. Astley, D.Gareth EvansAbstractThe incidence of breast cancer continues to increase worldwide. Population-based screening is available in many countries but may not be the most efficient use of resources, thus interest in risk-based/stratified screening has grown significantly in recent years. An important part of risk-based screening is the incorporation of mammographic density (MD) and single nucleotide polymorphisms (SNPs) into risk prediction models to be combined w...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - December 4, 2019 Category: OBGYN Source Type: research
Postpartum haemorrhage - multiple choice questions vol. 61
Publication date: November 2019Source: Best Practice & Research Clinical Obstetrics & Gynaecology, Volume 61Author(s): (Source: Best Practice and Research Clinical Obstetrics and Gynaecology)
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 26, 2019 Category: OBGYN Source Type: research
Immunology in obstetrics and gynaecology - Multiple choice answers vol. 60
Publication date: November 2019Source: Best Practice & Research Clinical Obstetrics & Gynaecology, Volume 61Author(s): (Source: Best Practice and Research Clinical Obstetrics and Gynaecology)
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 26, 2019 Category: OBGYN Source Type: research
Index
Publication date: November 2019Source: Best Practice & Research Clinical Obstetrics & Gynaecology, Volume 61Author(s): (Source: Best Practice and Research Clinical Obstetrics and Gynaecology)
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 26, 2019 Category: OBGYN Source Type: research
Editorial Board
Publication date: November 2019Source: Best Practice & Research Clinical Obstetrics & Gynaecology, Volume 61Author(s): (Source: Best Practice and Research Clinical Obstetrics and Gynaecology)
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 26, 2019 Category: OBGYN Source Type: research
Ovarian protection with gonadotropin-releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus
Publication date: Available online 13 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Ruba Kado, W. Joseph McCuneAbstractAdministration of cyclophosphamide (CYC), an alkylating agent used to treat malignancies and severe rheumatic diseases, creates a risk of ovarian insufficiency that is related to the intensity and duration of therapy and the age of the patient. To preserve reproductive capacity in the appropriate clinical setting, oocyte, embryo, and/or ovarian tissue cryopreservation are recommended. Medical protection with depot gonadotropin-releasing hormone agonists (GNRHa) h...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 26, 2019 Category: OBGYN Source Type: research
Long-term outcome of children born from mothers with autoimmune diseases
Publication date: Available online 13 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Cecilia Nalli, Jessica Galli, Maria Grazia Lazzaroni, Laura Andreoli, Elisa Fazzi, Angela TincaniAbstractAutoimmune diseases often affect young women and this may represent a problem in family planning. Pregnancies in these patients may carry several complications but nowadays the continued amelioration in treatment and management has greatly improved the pregnancy outcome. The main concern of these women obviously is the short- and long-term outcome of their children. A child born from a woman wi...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 25, 2019 Category: OBGYN Source Type: research
Breast cancer prevention in high risk women
Publication date: Available online 21 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Mangesh A. Thorat, Rajeshkumar BalasubramanianAbstractWomen at a high-risk of developing breast cancer are a heterogenous group of women including those with and without high-risk germline mutation/s. Prevention in these women requires a personalised and multidisciplinary approach. Preventive therapy with Selective oestrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors (AIs) substantially reduces breast cancer risk well beyond active treatment period. The importance of benig...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 21, 2019 Category: OBGYN Source Type: research
Chapter 9: Risk-based breast cancer screening strategies in women
Publication date: Available online 18 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Elaine F. Harkness, Susan M. Astley, D Gareth EvansAbstractThe incidence of breast cancer continues to increase worldwide. Population-based screening is available in many countries but may not be the most efficient use of resources, thus interest in risk-based/stratified screening has grown significantly in recent years. An important part of risk-based screening is the incorporation of mammographic density and single nucleotide polymorphisms (SNPs) into risk prediction models to be combined with c...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 19, 2019 Category: OBGYN Source Type: research
Medications in pregnancy and breastfeeding
Publication date: Available online 15 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Sofia Tosounidou, Caroline GordonAbstractAdvances in therapeutics, including a wider use of biologics and targeted synthetic disease modifying drugs (DMARDs) have substantially improved the management of rheumatic diseases, resulting in more women with severe disease considering pregnancy. Every clinical rheumatologist has encountered a woman who wishes to have a pregnancy - or who presents already pregnant - and who values the importance of reliable information on rheumatic diseases and safety of...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 16, 2019 Category: OBGYN Source Type: research
Ovarian protection with gonadotropin releasing hormone agonists during cyclophosphamide therapy in systemic lupus erythematosus
Publication date: Available online 13 November 2019Source: Best Practice & Research Clinical Obstetrics & GynaecologyAuthor(s): Ruba Kado, W. Joseph McCuneAbstractAdministration of cyclophosphamide (CYC), an alkylating agent used to treat malignancies and severe rheumatic diseases, creates a risk of ovarian insufficiency that is related to the intensity and duration of therapy and the age of the patient. To preserve reproductive capacity in the appropriate clinical setting, oocyte, embryo, and/or ovarian tissue cryopreservation are recommended. Medical protection with depot-gonadotropin releasing hormone agonists (GNRH-a) ...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - November 14, 2019 Category: OBGYN Source Type: research
